CR

CreoSG Co.,Ltd.

Offers IT solutions to financial institutions and develops vaccines for HIV and coronaviruses.

040350 | KO

Overview

Corporate Details

ISIN(s):
KR7040350001
LEI:
Country:
South Korea
Address:
서울특별시 강남구 테헤란로13길 31-1 4층(역삼동, 일리빌딩), 강남구
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

CreoSG Co., Ltd. operates as a diversified company with two primary business segments: IT solutions and biotechnology. The IT division specializes in developing and supplying software and next-generation systems for financial institutions, offering services that include application development, IT outsourcing, and infrastructure management. Concurrently, the company has a significant focus on the biotechnology sector, primarily conducting vaccine research and development. This division leverages a proprietary recombinant VSV (Vesicular Stomatitis Virus) vector platform technology to develop novel vaccines, with key projects targeting HIV/AIDS and various coronaviruses.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-19 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제3자배정-소액공모)
Korean 7.5 KB
2025-09-19 00:00
Share Issue/Capital Change
소액공모실적보고서
Korean 29.0 KB
2025-09-18 00:00
Major Shareholding Notification
최대주주변경을수반하는주식담보제공계약해제ㆍ취소등
Korean 19.8 KB
2025-09-11 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 51.0 KB
2025-09-11 00:00
Share Issue/Capital Change
소액공모공시서류(지분증권)
Korean 2.2 MB
2025-09-10 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 60.5 KB
2025-09-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 163.4 KB
2025-09-03 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 39.7 KB
2025-09-01 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득 (제22회차)
Korean 9.3 KB
2025-08-29 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 44.9 KB
2025-08-20 00:00
Regulatory News Service
불성실공시법인지정 (공시불이행)
Korean 6.1 KB
2025-08-14 00:00
Audit Report / Information
반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)
Korean 12.2 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.9 MB
2025-07-30 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 44.6 KB
2025-07-29 00:00
Regulatory News Service
불성실공시법인지정예고 (공시불이행)
Korean 5.0 KB

Automate Your Workflow. Get a real-time feed of all CreoSG Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CreoSG Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CreoSG Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.